IPP Bureau
Samsung Bioepis’ Pembrolizumab biosimilar SB27 meets phase 1 PK endpoints
By IPP Bureau - May 06, 2026
The proposed biosimilar to Keytruda demonstrated pharmacokinetic bioequivalence in a multicountry Phase 1 study involving non-small cell lung cancer patients
Ajanta Pharma Q4 FY26 revenue surges 21% to Rs 1,422 Crore; PAT climbs 18%
By IPP Bureau - May 06, 2026
FY26 revenue rises 17% to Rs 5,453 crore as US generics business jumps 49% and adjusted EBITDA margin improves to 26% for the quarter
Alkem Laboratories receives relief as GST demand of Rs 69.65 crore dropped on appeal
By IPP Bureau - May 06, 2026
The company informed stock exchanges that the appellate authority has set aside the GST demand along with applicable interest and penalty
Laurus Labs Q4 profit rises to Rs 279 crore, FY26 revenue up 23%
By IPP Bureau - May 06, 2026
The company reported robust revenue and profit growth for FY26, supported by strong CDMO performance, improving margins, and expansion across advanced manufacturing platforms
Biocon Biologics receives 5 procedural observations after US FDA inspection at Bengaluru facility
By IPP Bureau - May 06, 2026
The US FDA completed a pre-license inspection of Biocon Biologics’ biosimilars manufacturing site at Biocon Park between April 20 and April 29, 2026
Revvity tops Q1 estimates and unveils plans to exit China immunodiagnostics
By IPP Bureau - May 06, 2026
The company also announced a major portfolio shift, planning to divest its Immunodiagnostics business in China, a unit that generated approximately 6% of its fiscal 2025 revenue
Pfizer powers ahead in 2026 with strong Q1 results as pipeline momentum builds
By IPP Bureau - May 06, 2026
The pharmaceutical giant reported $14.5 billion in revenue, up 5% year-over-year, and reaffirmed its full-year outlook
Emcure crosses US$1 billion revenue milestone in FY26; PAT rises 33%
By IPP Bureau - May 06, 2026
Pharma major reports FY26 revenue of Rs 9,204 crore with 16.6% growth
Caplin Steriles receives USFDA approval for Calcium Gluconate Injection
By IPP Bureau - May 06, 2026
Fresenius Kabi's approved generic therapy addresses acute symptomatic hypocalcemia and targets a US market valued at nearly $71 million
DCDC Health Services expands dialysis network across Uttar Pradesh under PPP model
By IPP Bureau - May 06, 2026
The kidney care provider has established over 40 dialysis centres, delivering more than 40,000 dialysis sessions
MSD launches cervical cancer awareness campaign in India with Madhuri Dixit Nene
By IPP Bureau - May 06, 2026
The initiative aims to encourage women and parents to seek timely medical guidance on cervical cancer prevention and HPV awareness
Project Serotonin launches AI-powered gut health protocol
By IPP Bureau - May 06, 2026
The precision health platform integrates genetics, biomarkers, diet, and lifestyle data to deliver personalised gut health interventions and therapy support
Even Healthcare receives IRDAI approval to offer retail health insurance products
By IPP Bureau - May 06, 2026
The approval enables the company to directly sell health insurance plans to individuals and families while integrating its managed healthcare delivery model into retail offerings
PharmEasy launches AI-powered online physiotherapy service
By IPP Bureau - May 06, 2026
The platform offers personalised recovery plans, AI-driven movement tracking, and access to certified physiotherapists for more than 250 conditions
Govt launches Swasth Bharat portal to integrate India’s public health digital ecosystem
By IPP Bureau - May 06, 2026
ABDM-compliant platform aims to reduce data duplication, improve interoperability, and streamline healthcare delivery through a unified digital interface
